Genetic modification with the addition of the extracellular domains of PD-1 and CD137L (4-1BBL) led to a 70% long-term cure rate in a sub-cutaneous hepatocellular carcinoma (HCC) model (69). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.